Lyssenko, Valeriya
Vaag, Allan
Funding for this research was provided by:
Familien Hede Nielsens Fond
Novo Nordisk Fonden (NNF18OC0034440)
Bergens Forskningsstiftelse (BFS811294)
University of Bergen
Article History
Received: 17 January 2023
Accepted: 27 April 2023
First Online: 14 July 2023
Acknowledgments
: We thank I. Hanson (ExternalRef removed) for critical review of the preliminary draft of the paper.
: Open access funding provided by University of Bergen (incl Haukeland University Hospital) The work presented in this review was supported by the Swedish Research Council (Dnr2015-03574 and Dnr349-2006-237), Strategic Research Area Exodiab (Dnr2009-1039), the Novo Nordisk Foundation (NNF12OC1016467; NNF20OC0063292), the Swedish Foundation for Strategic Research (DnrIRC15-0067), the Steno Diabetes Center Copenhagen, the Bergen Research Foundation and Trond Mohn Foundation (BFS811294), the University of Bergen and the Hede Nielsen Foundation.
: The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: VL generated the first draft of the article. Both authors were responsible for drafting and editing the article and revising it critically for important intellectual content. Both authors approved the version to be published.